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The success of catheter ablation of atrial fibrillation 
(AF) remains modest despite the use of a variety of 
techniques, because the real target remains elusive.1 Even 
the endpoint of AF ablation is still under debate. It is not 
yet known whether isolation of the pulmonary veins 
(PVI), currently having a reproducible modest success 
rate when performed at the antrum and guided by 
electrophysiological mapping, is what is needed or 
additional foci should be routinely targeted. Some 
investigators have suggested that it is the ganglionated 
plexi (GPs) that mostly provide the triggers to the 
pulmonary veins, and GPs should be the primary targets 
during ablation.2 Others have focused on ablation of 
complex-fractionated atrial electrograms (CFAEs) 
claiming successful outcome;3 some have combined PVI 
with ablation of CFAEs.4 In cases of persistent AF, 
additional ablation lines and/or posterior atrial wall 
debulking have been applied to enhance the success rate 
of the procedure. Until recently, no focal ablation was 
ever reported to have any success in this patient 
population.  
Recently, Narayan et al devised an optical 
computational approach and mapped localized electrical 
rotors and focal impulse sources in 49 patients with AF. 
Patients with persistent AF (n=30) had more sources than 
those with paroxysmal AF (2.1±1.0 vs 1.5±0.8, P=0.02), 
related to shorter cycle length (163±19 ms vs 187±25 ms, 
P<0.001).5 The majority of sources were found in the left 
atrium and only about a quarter of sources were localized 
in the right atrium. In a subsequent case report, the 
authors presented a patient with persistent AF who failed 
prior left atrial radiofrequency Maze and endocardial 
ablation procedures.6 Use of this novel computational 
mapping disclosed one AF rotor in the right atrium and 
another in the left atrium. Brief 3–5-minute ablation 
applications at each rotor terminated AF, which remained 
noninducible on testing, while no AF recurrence was 
reported over the next 6 months.6 In another study by the 
same group, the investigators localized rotors or focal 
sources (mean 2.1 sources) in 98 (97%) of 101 patients 
with sustained AF and then proceeded with ablation 
aiming at these targets.7 This novel approach with focal 
impulse and rotor modulation (FIRM) was applied in 36 
patients and compared with conventional ablation 
performed in the other 71 patients. The endpoint of 
ablation was AF termination or consistent slowing, which 
was achieved in 86% of FIRM-guided cases versus 20% 
of conventional cases (p<0.001). FIRM ablation alone at 
the primary source terminated AF in a median 2.5 min. 
During follow-up (median 273 days), after a single 
procedure, 82% of FIRM-guided cases vs 45% of 
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conventional cases were free from AF. Adverse events 
were similar between the two groups. The authors 
concluded that AF is sustained by several meandering 
waves (rotors) or focal impulse sources and FIRM 
ablation at these specific sources acutely terminated or 
slowed AF, and improved outcome. In another small 
series of 12 patients, FIRM mapping identified focal AF 
sources (average of 1.9±0.8 per patient) in either atria and 
FIRM-guided ablation achieved AF termination (n=8) at 
about 5 minutes or AF organization (n=4). 8  
These recent reports by Narayan’s and other groups 
show, for the first time, stable rotors to be the drivers of 
AF and guided ablation of these drivers can result in 
termination of AF after a relatively short application.5-9 
Although it is not entirely clear whether the AF driver in 
these patients are focal discharge or rotors, the reports by 
Narayan et al,7 if and when reproduced by other teams, 
have the potential to revolutionize the field of AF 
ablation. Of course this entails a complex method of 
panoramic simultaneous mapping of electrical activation 
with use of a basket catheter and hence there will be 
hurdles in its applicability. However, this novel, albeit 
intricate, approach suggests that one or few drivers of AF, 
capable of maintaining AF, can be effectively identified 
and successfully eliminated by their targeted ablation.   
It remains unclear whether these rotors and focal 
sources could be identified by other means rather that this 
complex computational mapping. Nademanee et al 
introduced complex fractionated atrial electrograms 
(CFAEs) as ablation targets rather than PVI in patients 
with AF.3 In a cohort of 121 patients with refractory AF 
(57 paroxysmal and 64 chronic), CFAEs were found in 7 
of 9 regions of both atria, mostly in the interatrial septum, 
pulmonary veins, roof of left atrium, and left 
posteroseptal mitral annulus and coronary sinus ostium. 
Ablation at these areas resulted in termination of AF 
without need for cardioversion in 115 of the 121 patients 
(95%). At 1-year of follow-up, 110 (91%) patients were 
free of arrhythmia recurrence, 92 after one ablation 
procedure and 18 after two procedures. Sanders et al 
performed spectral analysis and endocardial mapping of 
dominant activation frequency (frequency with the 
highest amplitude) during AF in 32 patients undergoing 
AF ablation (19 paroxysmal, 13 permanent).10 Ablation at 
a dominant frequency site resulted in significant 
prolongation of the arrhythmia cycle length, while no 
change was observed in sites with absent dominant 
frequency. Importantly, AF terminated during ablation in 
17 of 19 patients with paroxysmal AF, but not permanent 
AF. The authors concluded that spectral analysis and 
frequency mapping can identify localized sites of high-
frequency activity during AF and ablation at these sites 
can result in prolongation of the AF cycle length and 
termination of paroxysmal AF, indicating their role in the 
maintenance of AF. Takahashi et al from Haissaguerre’s 
laboratory have also reported on focal ablation in a series 
of 40 patients with chronic AF.11 The investigators first 
performed PVI and roof line ablation; then, they 
proceeded with electrogram-based ablation in the left 
atrium and coronary sinus. The authors identified the 
percentage of continuous electrical activity and the 
presence of a temporal gradient of activation as 
independent predictors of favorable ablation regions They 
concluded that catheter ablation at sites displaying a 
greater percentage of continuous activity or a temporal 
activation gradient is associated with slowing or 
termination of chronic AF. These reports emphasize the 
importance of local electrogram analysis in the ablation 
process. Whether this type of analysis could offer some 
insight into the localization of focal sources or 
mechanisms of AF and direct focal ablation without the 
need of PVI or other complex procedures remains 
dubious for the time being.  
 The work with rotors and local drivers of AF goes 
back to several years, when investigators put forth the 
hypothesis that maintenance of AF, regardless whether it 
is paroxysmal or persistent, may depend on the periodic 
activity of a limited number of rotors in the left atrial-
pulmonary vein junction, which activate the atria at very 
high rates resulting in fibrillatory activity.12-14  High 
resolution optical mapping techniques allowed for 
experiments which have shown spatiotemporal 
organization during AF and in some cases rotors seem to 
be the drivers that maintain AF. Rotors may form when a 
wave breaks upon interacting in its path with the 
heterogenous structural and/or electrophysiological 
substrate. Thus, it seems that wavebreak, leading to 
wavelet formation and rotor initiation, is crucial for AF 
maintenance. There appears to be an ionic basis in the 
initiation, control and modification of rotors and 
fibrillatory conduction and termination, with involvement 
of both sodium and potassium currents.14 Experiments 
have indicated that inhibition of sodium current (INa) may 
induce rotor and AF termination by 3 different 
mechanisms (by enlarging the core of the rotor, 
decreasing rotor anchorage to functional obstacles leading 
to further meandering and final extinction, and by 
reducing the number of secondary wavelets that generate 
new rotors). Certain potassium currents (IKur and Ito) have 
also been suggested to prevent or interrupt AF, while 
others (Ik1 and IK,Ach) seem to enhance the arrhythmia. 
Interestingly, intravenous administration of adenosine has 
been shown to accelerate drivers of human AF. 15 Finally, 
structural remodeling has been shown to modify rotor 
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behavior, e.g. fibrosis in chronic heart failure has been 
shown to affect a stable rotor and lead to multiple 
unstable rotors and wave breaks.15  
The parasympathetic system seems to play an 
important role in AF promotion. Vagal stimulation 
decreases the action potential duration of atrial myocytes 
and produces hyperpolarization of atrial action potentials 
by inducing an acetylcholine-dependent K+ current, IKACh. 
In a recent study,16 vagal stimulation proved to be more 
effective than rapid atrial pacing in promoting AF 
maintenance. Both interventions have been reported to 
enhance inwardly rectifying K+ currents, i.e. the 
muscarinic receptor-activated IKACh in the case of vagal 
nerve stimulation, and the IK1 and IKACh,c currents in the 
case of atrial pacing. The main difference between the 
effects of vagal stimulation effects and atrial pacing is 
ICaL downregulation, which plays a main role in atrial 
pacing but is not produced by vagal nerve stimulation. 
The cardiac autonomic nervous system forms a complex 
neural network and converges at the ganglionated plexi 
(GP), embedded within epicardial fat pads, which 
modulate cardiac electrophysiology. Recent data indicate 
that activity of the intrinsic autonomic nervous system, 
particularly parasympathetic activation, may be critical 
for the initiation and maintenance of AF; it appears that 
focal firing from the pulmonary veins is effected via 
activation of the GPs adjacent to these veins.2 According 
to this proposal, it is the GPs associated with the 
pulmonary veins and not the pulmonary veins themselves 
that are important in the initiation of AF and that the 
interruption of axons from these hyperactive GPs to 
pulmonary veins may have mainly contributed to the 
procedural success of PVI.  
Recent data have also provided evidence that GP 
hyperactivity is responsible for CFAEs.4 Moreover, 
CFAEs can be provoked by acetylcholine-induced 
activation of the autonomic nervous system and thus may 
have an autonomic neural basis. Studies have indicated 
that the CFAEs are generally located at sites of the 
distribution of GPs. Thus, ablation of CFAEs and/or GPs 
can both be considered cardiac autonomic denervation. 
Adjunctive ablation of CFAEs and/or GPs has been 
proposed as strategies to increase the rate of AF cure. In a 
recent meta-analysis, PVI followed by CFAE/GP ablation 
was suggested as more effective in the maintenance of 
sinus rhythm compared with PVI alone.4 The working 
hypothesis is that AF triggers emanate from the 
pulmonary veins, while atrial substrate regions are mainly 
the presumed anatomic areas of CFAEs and GPs. Thus, 
PVI alone only eliminates the triggers of AF but when 
combined with CFAE/GP ablation, the atrial substrate is 
also modified. Nevertheless, CFAE/GP ablation alone 
was not superior to PVI alone after a single procedure, 
especially in patients with paroxysmal AF. In paroxysmal 
AF patients, the trigger mechanism appears more 
responsible for the development of AF. Thus, PVI can 
eliminate triggers of AF and CFAE/GP ablation mainly 
changes the maintenance mechanism. PVI ablation is 
preferable in paroxysmal AF, while the combination 
therapy would be desirable in patients with persistent or 
chronic AF. Another form of autonomic denervation, 
renal artery denervation via radiofrequency ablation, has 
recently been clinically applied, mainly for refractory 
hypertensive patients, but this has also preliminarily been 
tested in patients with AF, as well. In a recent study, 
among 27 patients, 14 were randomized to PVI only, and 
13 to PVI with renal artery denervation. At 12 months, 
significant reductions in systolic and diastolic blood 
pressure were recorded only in patients treated with PVI 
with renal denervation, but 9 of the 13 patients (69%) 
treated with PVI with renal denervation were AF-free 
versus 4 (29%) of 14 patients in the PVI-only group (p = 
0.033). 17   
Current working hypotheses give emphasis on the 
sources (of automatic, triggered or reentrant mechanisms) 
that are identified in the pulmonary veins as initiating the 
arrhythmia, and mechanism(s) of arrhythmia maintenance 
within the atria, the source of which has remained 
elusive. Achieving a precise localization of the source(s) 
responsible for AF maintenance would lead to finally 
solving the puzzle of the AF mechanism with an 
integrated approach to therapy or even prevention of this 
most common cardiac arrhythmia. The role of rotors and 
focal sources as a mechanism of AF perpetuation has 
recently been demonstrated by acute AF termination by 
brief FIRM ablation alone. This novel, practical and 
effective technique of AF ablation changes our 
conceptual model for AF and opens the possibility for 
patient-tailored approach. Of course, this needs validation 
in larger populations, by other investigators, and in 
randomized trials, before being finally adopted. 
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In the early 1990s the concept of transcatheter aortic 
valve implantation (TAVI) appeared challenging and 
totally unrealistic. It was a true “resurrection” for Cribier 
and his whole team1 performing the first TAVI in an 
inoperable patient in 2002, using a transeptal antegrade 
approach and balloon-expandable aortic valve prosthesis. 
Since then TAVI has been performed in more than 50000 
patients worldwide. TAVI is currently indicated in 
patients with severe symptomatic aortic stenosis (AS) and 
acceptable life expectancy who are not suitable for aortic 
valve replacement (AVR) (indication class IB) or as an 
alternative to aortic valve replacement (AVR) in 
selected high-risk operable patients (class IIB), according 
to the “Heart Team” assessment.2   
The TAVI Heart Team comprised of clinical 
cardiologists, interventionalists, surgeons, anaesthetists 
and imaging specialists with expertise in the treatment of 
valve disease, selects patients suitable for TAVI taking 
into account advantages and disadvantages of both AVR 
and TAVI. A logistic EuroSCORE ≥20% (logistic 
EuroSCORE I tends to overestimate observed mortality 
risk by a factor of 2 to 3 and a newly updated logistic 
EuroSCORE II is currently available in clinical practice) 
or a Society of Thoracic Surgeons (STS) score >10% 
are suggested as indications for TAVI therapy.3 Recent 
publications have identified a number of baseline 
variables independently associated with mortality or poor 
outcome in patients undergoing TAVI (low body mass, 
functional status, left ventricular dysfunction, NT-
proBNP, prior stroke, diabetes, chronic kidney disease, 
anemia, severe tricuspid and mitral regurgitation, 
porcelain aorta or history of chest radiation) which could 
be integrated into new scoring systems to quantify and 
predict the prognosis of TAVI both in the immediate and 
in the long term (Table 1).4 Apart from certain absolute 
and relative contraindications for TAVI (Table 2)2 a 
number of subgroups require more precise evaluation, for 
example transcatheter ‘valve in a valve’ appears as an 
attractive alternative in bioprosthesis failure with more 
than 100 successful TAV-in-surgical aortic valve 
procedures already been performed.5,6 Several successful 
case reports document stenotic bicuspid aortic valves 
been treated with TAVI and according to a German 
